Novo Inks $2.6B License For Once-Weekly GLP-1 Pill
Novo Nordisk said Tuesday that it will pay Hengrui Pharma up to $2.6 billion for the right to market a GLP-1 weight loss pill that patients could potentially take just once...To view the full article, register now.
Already a subscriber? Click here to view full article